3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study

Kamdar M, Solomon SR, Arnason J, et al

In this article, the authors report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel versus standard of care for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma. These results confirmed superior and more durable efficacy with lisocabtagene maraleucel versus standard of care, support lisocabtagene maraleucel as an effective second-line treatment for relapsed/refractory LBCL.